Skip to content
Homepage
Author:
Zealand Pharma
Posted Date:
October 19, 2026
Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830
Zealand Pharma
October 19, 2026
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Zealand Pharma
October 13, 2026
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
Zealand Pharma
October 1, 2026
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Zealand Pharma
October 1, 2026
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
Zealand Pharma
September 29, 2026
Zealand Pharma – Transactions related to share buy-back program (week 39, 2026)
Zealand Pharma
September 28, 2026
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity
Zealand Pharma
September 22, 2026
Zealand Pharma – Transactions related to share buy-back program (week 38, 2026)
Zealand Pharma
September 21, 2026
Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
Zealand Pharma
September 18, 2026
Zealand Pharma – Transactions related to share buy-back program (week 37, 2026)
Zealand Pharma
September 14, 2026
1
2
3
4
Next
